Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

-RAS mutations.

"Previous preclinical data indicates that reovirus tends to localize in the lungs, and we have seen clinical responses in metastatic lung lesions with REOLYSIN(R) as a monotherapy or in combination with paclitaxel and carboplatin," said Dr. Brad Thompson, President and CEO of Oncolytics. "A significant clinical opportunity for REOLYSIN(R) is in the treatment of patients with metastatic cancers including NSCLC who have a mutated K-RAS gene and are unlikely to respond to treatment with EGF receptor inhibitors."

About Lung Cancer

Lung cancer is the second most common cancer in men and women and is the leading cause of cancer death. More people die of lung cancer than of colon, breast and prostate cancers combined. During 2008, there will be about 215,020 new cases of lung cancer in the U.S., of which 85% to 90% will be NSCLC. Only about 15% of people diagnosed with lung cancer are still alive after five years. There is no single, first-line therapy approved for NSCLC in the U.S., but first-line combination treatments include avastin/paclitaxel/carboplatin, vinorelbin/cisplatin, gemcitabine/cisplatin, paclitaxel/cisplatin and docetaxel/cisplatin. Other therapies approved for second and third-line treatments are used as well. For more information about lung cancer, please go to http://www.cancer.org.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking state
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/19/2014)... September 19, 2014 The new , ... , available today on PharmaBoardroom.com for ... crisis that rocked the Spanish economy in 2009, and the ... community has remained pragmatic in times of trouble. ... the fifth biggest European market, and the general conditions to ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... (Nasdaq: SGMO ) today reported second quarter 2011 ... quarter ended June 30, 2011, Sangamo reported a consolidated net ... a net loss of $3.9  million, or $0.09 per share, ... 2011, the company had cash, cash equivalents and marketable securities ...
... 2011 Once routinely discarded during the birth process, ... life-saving stem cells that can be collected and stored ... and vast medical potential, published data shows that three ... about cord blood banking. In connection with ...
... Calif., July 26, 2011 Synterra Energy, Inc. ... and assets for waste biomass conversion from Pacific ... Lion Bio-Energy (Toledo, Ohio).  With the merger, Synterra ... bio-refineries for the economic production of renewable fuels, ...
Cached Biology Technology:Sangamo BioSciences Reports Second Quarter 2011 Financial Results 2Sangamo BioSciences Reports Second Quarter 2011 Financial Results 3Sangamo BioSciences Reports Second Quarter 2011 Financial Results 4Sangamo BioSciences Reports Second Quarter 2011 Financial Results 5Sangamo BioSciences Reports Second Quarter 2011 Financial Results 6Sangamo BioSciences Reports Second Quarter 2011 Financial Results 7Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 2Parent's Guide to Cord Blood Foundation Launches Nation's First Searchable Map of U.S. Sites for Donating Umbilical Cord Blood 3Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery 2
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening program ... few short months, earning it the first-ever Newborn Screening Quality ... of Dimes presented Will Humble, M.P.H., Arizona,s Department of Health ... today. Mr. Humble established a policy of full transparency for ... newborn blood samples to the lab for analysis, and set ...
(Date:9/18/2014)... of carbon and nitrogen comprise all spheres of ... systems have caused imbalances and perturbations that resulted ... Increased GHGs result in climate changes which influence ... and the atmosphere. Understanding these feedback mechanisms has ... environmental science during the past three decades. , ...
(Date:9/18/2014)... can swim up to 400 kilometres in search of a ... change. , Clownfish spend their entire adult lives under the ... wander the open ocean, says study co-author, Dr Hugo Harrison ... (Coral CoE) at James Cook University. , "In the past ... given a rare glimpse into how far they can swim, ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2
... A team led by researchers at the University ... the "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is ... is well known for causing difficult-to-treat and potentially fatal ... 1990s it has also been infecting otherwise healthy people ...
... study shows for the first time that episodes of ... the 2001-02 drought, greatly accelerated development of the mountain ... to chart the evolution of the current pine beetle ... beetle outbreak in the two primary host species, the ...
... a daily multivitamin, but little is known about a multivitamin,s ... Brigham and Women,s Hospital (BWH) finds that daily multivitamin use ... A similar BWH study, announced last month, found daily ... 8 percent. The cardiovascular disease findings will be presented ...
Cached Biology News:Superbug MRSA identified in US wastewater treatment plants 22001-2002 drought helped propel mountain pine beetle epidemic, says CU study 22001-2002 drought helped propel mountain pine beetle epidemic, says CU study 32001-2002 drought helped propel mountain pine beetle epidemic, says CU study 4Daily multivitamin use does not reduce cardiovascular disease risk in men 2
... SNPstream System Delivers 4,600 to Over 3 ... Genotyping System is capable of performing 4,600 ... Part of the GenomeLab family of products*, ... up to 48 SNPs in each well ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Mouse monoclonal antibody to DCAMKL2 - doublecortin and CaM kinase-like 2...
... Tube Disperser System from IKA Works is the ... cleaner, safer, and more efficient way to disperse ... 2 to 15 ml inside sealed tubes. Depending ... of 4 different tube types. Each tube is ...
Biology Products: